Scantox expanded its value chain in early April by acquiring QPS Neuropharmacology, adding unique and market-leading central nervous system (CNS) research capabilities. In this blog post, Manuela Prokesch (COO of Discovery) and Andy Brown (CCO) discuss the impact of the Scantox Neuro drug discovery team. They explain how this acquisition enhances Scantox’s service solutions, enabling neuroscience drug developers to advance their lead candidates through the pipeline.
What key elements have been crucial in shaping Scantox Neuro into a unique and leading organization within the neuroscience industry?
Manuela: Scantox Neuro has established a distinct presence in the neuroscience research industry through strategic initiatives that broadened our research scope. We now encompass an extensive range of neurological conditions for both in vitro assays and in vivo animal models. To support this expansion, we strategically hired business development staff with robust scientific backgrounds. Direct scientist-to-scientist communication ensures our customers receive accurate and actionable information about what to expect from the start. Our “science-first approach” is also reflected in our process of generating detailed in-house data. Unlike many competitors, we transparently communicate how our experimental systems are validated, ensuring your results’ reliability and accuracy. Each study at Scantox is custom-built and meticulously tailored to meet each client’s needs.
Andy: Our recognition in the neuro drug discovery field stems from our expertise in specific neuro-related disease areas and a consistent track record of validated in vitro and in vivo models. This rigorous scientific validation sets us apart and provides a benchmark in the industry. Its dedication to scientific excellence makes Scantox Neuro the preferred partner for drug developers.
How does Scantox’s approach compare with the competitive landscape?
Manuela: Our clients consistently return to us because of the genuine connections we build, making us feel more like an extension of their team rather than just a service provider. We also extend this same level of care to the animals involved in our studies, and clients appreciate our commitment to animal welfare. This combination of high-quality scientific work and clear values fosters loyalty and long-term business relationships.
Andy: Complementing Manuela’s points about our client relationships, our operational agility allows us to start projects within weeks, not months. This swift responsiveness means we can join client teams early, bringing decades of experience and a guided, personalized approach to each project. This capacity for quick integration and our hands-on approach offers a distinct advantage over more prominent organizations.
How has the Austrian neuro team demonstrated its cultural fit with Scantox?
Manuela: Over the past six months, we’ve seen a strong cultural alignment within our teams, unified by shared experiences and mutual values. This acquisition hasn’t just met its goals; it’s created an environment where we operate as one cohesive team with a shared vision. Our commitment to accountability ensures that we continue to build partnerships founded on mutual respect and excellence.
Andy: Maintaining the customer-centric nature of our team was crucial, and it aligns perfectly with the Scandinavian values at Scantox. The high dedication I’ve witnessed within our team inspires confidence that we’re well-equipped to help drug development leaders navigate new challenges and opportunities.
What can drug developers expect from our team?
Andy: We are now better equipped than ever to support you from the early stages of drug development to Investigational New Drug (IND)-enabling capabilities with a deep understanding of neurological diseases. All this while still getting timely reports, accurate scientific interpretations, and clear communication, empowering drug developers to make informed decisions.
Manuela: Whether you are a startup or an established pharmaceutical company, you receive the same high level of service. Our robust in-house CNS capabilities and thorough understanding of our models ensure that you benefit from our collective expertise. We are committed to supporting your journey at every step, helping you overcome scientific challenges by offering solutions that may not have been previously considered.
As we move forward under our new logo and name, rest assured that it’s the same dedicated team – now even better equipped to push the boundaries of what’s possible in neuroscience.
Discover how, together, we can turn your scientific challenges into solutions!
